To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome.
The bill’s titles are written by its sponsor.
Sep 14, 2016
114th Congress, 2015–2017
Died in a previous Congress
This bill was introduced on September 14, 2016, in a previous session of Congress, but was not enacted.
Representative for California's 52nd congressional district
Read Text »
Last Updated: Sep 14, 2016
Length: 2 pages
This is the first step in the legislative process.
H.R. 6033 (114th) was a bill in the United States Congress.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
Civic Impulse. (2017). H.R. 6033 — 114th Congress: Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act. Retrieved from https://www.govtrack.us/congress/bills/114/hr6033
“H.R. 6033 — 114th Congress: Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act.” www.GovTrack.us. 2016. April 30, 2017 <https://www.govtrack.us/congress/bills/114/hr6033>
|title=H.R. 6033 (114th)
|accessdate=April 30, 2017
|author=114th Congress (2016)
|date=September 14, 2016
|quote=Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act